Sharifudin, A
That is a meaningful shift for the clinical compounding ecosystem but it is not the same as FDA approval of a finished drug product
Expecting permanent "whitening" on a fixed timeline
Indeed, we can argue that the effectiveness, easy applicability, safe clinical profile and mechanism of BPC 157 (i.eBPC 157/dopamine/glutamate/NO system) represent an alternative, likely successful, future therapeutic direction for neurological conditions. Additional studies have shown that BPC 157 can offer tendon, ligament, and skeletal muscle healing (Gwyer, et al, 2019) it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments
Substantially longer than GHRP-6 and GHRP-2s 1560 minute half-lives
J., Otsa, K., Aakre, O., Villaggio, B., Capellino, S., & Straub, R